Posttransplant Lymphoproliferative Disorders in Liver Transplantation

Jain, Ashok Kumar; Nalesnik, M; Reyes, Jorgé; Pokharna, Renu; Mazariegos, George; Green, Michael; Eghtesad, Bijan; Marsh, Wallace; Cacciarelli, Thomas V.; Fontes, Paulo; Abu‐Elmagd, Kareem; Sindhi, Rakesh; Demetris, Jake; Fung, John J.

doi:10.1097/00000658-200210000-00005

Cited by 209 publications

(203 citation statements)

References 43 publications

Supporting

Mentioning

180

Contrasting

Unclassified

Order By: Relevance

“…In agreement with our observation, two recent single-center studies similarly reported no effect of time to tumor development on patient survival (38,39). Several reports have suggested differences between the clinical and biological characteristics of lymphomas that develop early or late after transplantation.…”

Section: Lymphomas After Solid Organ Transplantationsupporting

confidence: 93%

Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report

Opelz

Döhler

2004

American Journal of Transplantation

977

787

View full text Add to dashboard Cite

We used the Collaborative Transplant Study database to analyze the incidence, risk, and impact of malignant lymphomas in approximately 200 000 organ transplant recipients. Over a 10-year period, the risk in renal transplant recipients was 11.8-fold higher than that in a matched nontransplanted population (p < < 0.0001). The majority of lymphomas were diagnosed after the first post-transplant year. Heart-lung transplants showed the highest relative risk (RR 239.5) among different types of organ transplants. In kidney recipients, immunosuppression with cyclosporine did not confer added risk compared with azathioprine/steroid treatment, whereas treatment with FK506 increased the risk approximately twofold. Induction therapy with OKT3 or ATG, but not with anti-IL2 receptor antibodies, increased the risk of lymphoma during the first year. Antirejection therapy with OKT3 or ATG also increased the risk. First-year mortality in renal and heart transplant patients with lymphoma was approximately 40% and 50%, respectively, and showed no improvement in recent years. A pattern of preferential localization to the vicinity of the transplant was noted, and the prognosis of the patient was related to localization. This study highlights the continuing risk for lymphoma with time post-transplantation, the contribution of immunosuppression to increased risk, and continuing poor outcomes in patients with post-transplant lymphoma.

show abstract

Section: Lymphomas After Solid Organ Transplantationsupporting

confidence: 93%

Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report

Opelz

Döhler

2004

American Journal of Transplantation

977

787

View full text Add to dashboard Cite

show abstract

“…In literature, PTLD has been reported to occur months or years after transplantation. The experiences of multicenter clinical studies in the European transplant centers support the use of mTOR inhibitors in the management of PTLD following renal transplantation, with a reported PTLD incidence of 1%-10% in adults and 9.7% in children (19,25,26). In our study, 13 (6.3 %) of the 206 pediatric patients developed de novo malignancies post-transplantation, and the mean time to the occurrence of PTLD was 37.7±26.6 months.…”

Section: Discussionsupporting

confidence: 60%

“…EBV infection and immunosuppression therapy are the most important risk factors for PTLD. The incidence of PTLD depends on several factors: the age of the transplant recipient, duration of post-transplant immunosuppression or types of immunosuppressants used, and EBV infection (18,19). Reduction or cessation of immunosuppression is the most common initial approach for the development of PTLD.…”

Section: Discussionmentioning

confidence: 99%

Post-transplant malignancies in pediatric liver transplant recipients: Experience of two centers in Turkey

Karakoyun¹,

Onen²,

Baran³

et al. 2018

Turk J Gastroenterol

View full text Add to dashboard Cite

Results: In the study group, de novo cancer was diagnosed in 13 of the 206 patients. Post-transplant lymphoproliferative disease (PTLD) occurred in seven (53.8%) patients and other malignancies in six of the 13 patients. The types of PTLD were as follows: B-cell origin (n=2), Epstein-Barr virus (EBV)-related (n=2), T-cell origin (n=1), and Hodgkin's lymphoma (n=2). EBV DNA was isolated from seven patients, three of whom developed PTLD. The others developed

show abstract

“…In the previously reported study from the University of Pittsburgh of PTLD in 4000 patients who were followed for nearly 20 years, the rate of PTLD decreased with time, and the children had a higher incidence than the adults. 37 …”

Section: Ptld In Relation To the Age And Length Of Follow-upmentioning

confidence: 99%

Incidence of de novo cancer and lymphoproliferative disorders after liver transplantation in relation to age and duration of follow-up

2008

Self Cite

View full text Add to dashboard Cite

Posttransplant Lymphoproliferative Disorders in Liver Transplantation

Cited by 209 publications

References 43 publications

Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report

Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report

Post-transplant malignancies in pediatric liver transplant recipients: Experience of two centers in Turkey

Incidence of de novo cancer and lymphoproliferative disorders after liver transplantation in relation to age and duration of follow-up

Contact Info

Product

Resources

About